Welcome to the web site of the Italian Registry of Myelofibrosis with myeloid Metaplasia (RIMM).
The RIMM is a virtual community (network) of physicians and pathologists who cooperate to the care of patients with myelofibrosis nationwide.
Since 1999 the RIMM is working in order to guarantee to all the new cases of myelofibrosis the best quality in diagnosis, prognosis and therapy.
Furthermore, the RIMM has greatly contributed to the progression of knwoledge of this disease: the Registry has proposed the peripheral blood CD34+ cell count as a useful diagnostic and prognostic marker (Barosi et al, Blood 2002).
The RIMM has also conducted the largest clinical trial of patients with myelofibrosis, that verified thalidomide clinical usefulness in patients with anemia and/or thrombocythopenia (Barosi et al, Br J Haematol 2001; Barosi et al Leuk Lymph 2002; Marchetti et al, J Clin Oncol 2004).
Finally, the RIMM collaborates to a European network of research onto myeloproliferative disorders EUMNET, sponsored by a IVth Framework UE Project. Moreover, a collaboration has been started with the National Cancer Institute (NCI), in a project named MPD-RC – Myeloproliferative Disorders Research Consortium.